EMA Calls for Transparency, Collaboration in COVID-19 Studies

The European Medicines Agency (EMA) is urging transparency and collaboration on COVID-19 studies to facilitate more robust results.

“High-quality observational research of real world data collected during the pandemic can be an important complement to the results of randomised clinical trials in providing evidence on the safety and effectiveness of vaccines and treatments for COVID-19,” EMA says in a press release.

To read the full press release on EMA’s website, click here.